Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Heidi L. Holmberg"'
Autor:
Jens Buchardt, Heidi L. Holmberg, Johan Karlsson, Mads Kjelgaard-Hansen, Kasper Lamberth, Anders B. Sorensen, Wolfram Ruf, Prafull S. Gandhi, Carsten Dan Ley, Brit B. Sørensen, Anders Lærke Nielsen, Henrik Østergaard, Ole Hvilsted Olsen
Publikováno v:
Proceedings of the National Academy of Sciences. 114:12454-12459
Recombinant factor VIIa (FVIIa) variants with increased activity offer the promise to improve the treatment of bleeding episodes in patients with inhibitor-complicated hemophilia. Here, an approach was adopted to enhance the activity of FVIIa by sele
Autor:
Donald F. Brophy, Heidi L. Holmberg, Thomas Egebjerg, Helle Demuth, Mari Enoksson, Jens Buchardt, Thomas N. Krogh, Mette S Jensen, Marianne Kjalke, Erika J. Martin, Mads Kjelgaard-Hansen, Ida Hilden, Annika Sanfridson
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCES. 18(1)
Background Recombinant factor VIIa (rFVIIa) enhances thrombin generation in a platelet-dependent manner; however, rFVIIa binds activated platelets with relatively low affinity. Triggering receptor expressed on myeloid cells (TREM)-like transcript (TL
Autor:
Erika J. Martin, Janice Kuhn, M. E. Nolte, John C. Barrett, Rune Salbo, Donald F. Brophy, Emily K. Waters, Jacob Lund, Heidi L. Holmberg, Bo Wiinberg, Bassem M. Mohammed
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 23(6)
Introduction The thrombomodulin (TM)/activated protein C (APC) system is a key regulator of haemostasis, limiting amplification and propagation of the formed blood clot to the injury site. Dampening APC's inhibition of factor V (FV) and factor VIII (
Autor:
Stine Kjellev, Jais Rose Bjelke, Heidi L. Holmberg, Carsten Dan Ley, Mette B. Hermit, Ida Hilden, Thomas Lindebo Holm, Daniel Elenius, Mette Loftager
Publikováno v:
Blood. 134:3631-3631
People with haemophilia A (HA) lack functional factor VIII (FVIII) and typically receive FVIII replacement therapy to prevent or treat bleeds. However, this requires frequent i.v. access, and efficacy is impaired in inhibitor patients. Mim8 is in dev
Autor:
Søren E. Bjørn, D. M. Karpf, Henning R. Stennicke, Mirella Ezban, Torben Elm, Heidi L. Holmberg, Mikael Tranholm
Publikováno v:
Journal of Thrombosis and Haemostasis. 9:1070-1072
Autor:
Christina Jespersgaard, Flemming Möller, Torben Elm, Wendy Kappers, Mikael Tranholm, Bernd Peschke, Henning R. Stennicke, Hermann Pelzer, Ditte M. Karpf, Anne K. Kristensen, Ida Hilden, Mirella Ezban, Are Bogsnes, Heidi L. Holmberg, Egon Persson, Anette A. Pedersen, Peter B. Johansen, Henrik Rahbek-Nielsen, Lars Thim, Eva H. N. Olsen, Kristine Øvlisen, Frederik Rode, C. N. Gudme, Søren E. Bjørn, Kristoffer W. Balling, Marianne Kjalke
Publikováno v:
Blood. 121(11)
Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a longer half-life was developed without changing the protein structure. FVIII
Publikováno v:
Laboratory animals. 45(2)
Blood collection in mice can be a challenge, in particular for samples used for coagulation analysis as initiation of coagulation during the procedures can influence the results. Blood collection from the retrobulbar venous plexus is commonly used bu
Autor:
Søren E. Bjørn, Andreas Velsing Groth, Ditte M. Karpf, Brit B. Sørensen, Britta V. Bysted, Heidi L. Holmberg, Henning R. Stennicke, Mette B. Hermit, Mikael Tranholm
Publikováno v:
Thrombosis research. 128(2)
Introduction Bleeding episodes in haemophilia patients with inhibitors are primarily treated with by-passing agents such as recombinant activated FVII (rFVIIa). Prophylactic treatment with rFVIIa has been shown to significantly reduce the number of b
Autor:
Jacob Marsvin Laurberg, Jonas Heilskov Graversen, Søren K. Moestrup, Heidi L. Holmberg, Erling Falk
Publikováno v:
Laurberg, J M, Graversen, J H, Moestrup, S K, Holmberg, H L & Falk, E 2007, ' Acute Passivation of vulnerable plaques with wild-type apolipoprotein A-I in apoE-deficient mice. ', Vascular Disease Prevention, vol. 4, pp. 314-21 .
Laurberg, J M, Graversen, J H, Moestrup, S K, Holmberg, H L & E., F 2007, ' Acute Passivation of Vulnerable Plaques with Wild-Type Apolipoprotein A-I in ApoE-Deficient Mice ', Vascular Disease Prevention, vol. 4, no. 4, pp. 314-321 . https://doi.org/10.2174/1567270010704040314
Laurberg, J M, Graversen, J H, Moestrup, S K, Holmberg, H L & E., F 2007, ' Acute Passivation of Vulnerable Plaques with Wild-Type Apolipoprotein A-I in ApoE-Deficient Mice ', Vascular Disease Prevention, vol. 4, no. 4, pp. 314-321 . https://doi.org/10.2174/1567270010704040314
Objective: The apolipoprotein A-I (apoA-I) variant apoA-IMilano has rapid passivating effects on atherosclerotic plaques. In this study we tested if human wild-type apoA-I can likewise rapidly mobilize cholesterol and reduce inflammation and lipid co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a5bf3e1a54286e6c4d8fd024d5b7923
https://pure.au.dk/portal/da/publications/acute-passivation-of-vulnerable-plaques-with-wildtype-apolipoprotein-ai-in-apoedeficient-mice(a1d9c220-e123-11dc-9afb-000ea68e967b).html
https://pure.au.dk/portal/da/publications/acute-passivation-of-vulnerable-plaques-with-wildtype-apolipoprotein-ai-in-apoedeficient-mice(a1d9c220-e123-11dc-9afb-000ea68e967b).html
Autor:
Marianne Kjalke, Gert Bolt, Ditte M. Karpf, Heidi L. Holmberg, Laust Bruun Johnsen, Lars Thim, Ida Hilden, Johan Karlsson, Mikael Koefoed-Hansen, Henning R. Stennicke, Christina Jespersgaard, Hermann Pelzer
Publikováno v:
Blood. 118:1182-1182
Abstract 1182 VWF protects FVIII from clearance in the circulation and is believed to ensure location of platelets to the site of injury. However, it is unknown if binding of FVIII to VWF has a role in localizing and thereby also facilitating the eff